Table 1 Baseline characteristics of the total study cohort as well as stratified according to glypican-4 quartiles.
From: Evaluation of the association of serum glypican-4 with prevalent and future kidney function
Total cohort (n = 456) | Quartile 1 (n = 113) | Quartile 2 (n = 115) | Quartile 3 (n = 114) | Quartile 4 (n = 114) | P-value | |
|---|---|---|---|---|---|---|
Glypican-4, ng/mL | 5.5 [4.6–6.9] | 4.2 [3.9–4.3] | 5.0 [4.8–5.3] | 6.0 [5.7–6.4] | 7.9 [7.3–9.1] | – |
Age, years | 65 [57–72] | 59 [52–66.5] | 63 [56–70] | 67 [58–73] | 70 [62–75] | < 0.001 |
Male sex, % (n) | 62.7 (286) | 65.5 (74) | 65.2 (75) | 61.4 (70) | 58.8 (67) | 0.238 |
History of smoking | 55.9 (255) | 59.3 (67) | 60.9 (70) | 55.3 (63) | 48.2 (55) | 0.063 |
Body mass index, kg/m2 | 27.4 [25.2–30.1] | 26.9 [24.9–29.4] | 26.5 [24.7–29.4] | 27.8 [25.4–30.6] | 28.4 [26.1–31.8] | < 0.001 |
Hypertension, % (n) | 79 (360) | 78.8 [89] | 80.9 [93] | 71.9 [82] | 84.3 [96] | 0.837 |
T2DM, % (n)† | 22.9 (104) | 18.8 (21) | 23.5 (27) | 24.6 (28) | 24.6 (28) | 0.297 |
Total cholesterol, mg/dL†† | 195 [164–225] | 198 [162–235] | 197 [174–221] | 195 [166–229] | 190 [163–221] | 0.227 |
Significant CAD, % (n) | 53.1 (242) | 56.6 (64) | 54.8 (63) | 47.4 (54) | 53.5 (61) | 0.423 |
eGFR, mL/min/1.73 m2 | 88 [74.9–96.5] | 93 [85–101] | 91 [84–98] | 88 [73–95] | 73 [62–85] | < 0.001 |
eGFR < 60 mL/min/1.73 m2, % (n) | 7.2 (33) | 0.9 (1) | 0.0 (0) | 7.0 (8) | 21.1 (24) | < 0.001 |
ACR, mg/g | 13.0 [7.3–26.4] | 10.1 [6.1–21.4] | 10.9 [7.2–18.2] | 17.6 [9.1–32.7] | 16.2 [7.8–38.3] | < 0.001 |
Albuminuria, % (n) | 99 (21.7) | 14.2 (16) | 13.9 (16) | 27.2 (31) | 31.6 (36) | < 0.001 |
Chronic kidney disease, % (n) | 25.2 (115) | 15.0 [17] | 13.9 [16] | 30.7 [35] | 41.2 [47] | < 0.001 |
Statin use | 52.9 (241) | 59.3 (67) | 49.6 (57) | 53.5 (61) | 49.1 (56) | 0.207 |
Beta blocker use | 56.8 (259) | 61.1 (69) | 52.2 (60) | 54.4 (62) | 59.6 (68) | 0.928 |
ACE inhibitor use | 27.4 (125) | 25.7 (29) | 28.7 (33) | 24.6 (28) | 30.7 (35) | 0.559 |
